What We Do
Our Approach
What We Do

As a hospital membership organization, Colloquium member hospitals put on informative webinars. Topics are chosen by the member hospitals themselves and are usually related to sharing best practices, accreditation milestone development, and breaking news affecting heart failure. The Colloquium’s Heart Failure Webinar Series is open to others interested in improving heart failure care processes.

Below is a listing of upcoming webinars along with a sample listing of past presentations.


Members: Members have access to upcoming seminars by invitation or by contacting the Colloquium office at colloquiumhealth.com/contact. Members may access recorded seminars through the Member Portal.

Non-Members: If you are not yet a member of the Colloquium but would like to take part in an upcoming or recorded webinar, write us at colloquiumhealth.com/contact.

Transforming Health Care Leadership – A Systems Guide for Improving Patient Care, Lowering Per Capita Cost and Improving Population Health

September 25, 2013 (Wednesday) Noon to 1:00 pm (ET)


Dr. Michael Maccoby, The Maccoby Group
C. Jane Norman, Profound Knowledge Products, Inc.

To improve patient care, decrease costs and improve population health, health care organizations must become learning organizations. And this requires leadership teams equipped with strategic intelligence and profound knowledge.

Transforming Health Care Leadership describes what it takes to turn bureaucracies into learning organizations. It provides the tools leaders can employ and presents illustrative cases of health care organizations that have become learning organizations.

Learn More
Real-Time Predictive Analytics for Personalized Patient Care

August 28, 2013 (Wednesday) Noon to 1:00 pm (ET)


Dan Haber, Market Manager, Battelle Health & Analytics
Steve Rust, Sr. Research Leader, Battelle Health & Analytics

An overview of the role that analytical systems can play in optimizing individual patient care and resource effectiveness with comparisons to systems successfully employed in other domains such as aviation.

Learn More
Medication Therapy in Heart Failure

July 31, 2013 (Wednesday) Noon to 1:00 pm (ET)


Lori Wetmore, PharmD, BCPS, Cardiovascular Clinical Pharmacist, IU Health Arnett Hospital

Optimal medical therapy in heart failure (HF) has been shown to reduce morbidity and mortality. In addition, multiple co-morbidities contribute to an increasingly complex medication list. In this webinar, Lori Wetmore, Cardiovascular Clinical Pharmacist will review current medication recommendations from the 2013 ACCF/AHA Heart Failure Guideline update, as well as discuss those medications which can worsen or lead to HF.

Learn More
Reducing Heart Failure Readmissions at Lower Cost: The Promise and Peril of Technology?

June 26, 2013 (Wednesday) Noon to 1:00 pm (ET)


Jeffrey J Geppert, Research Leader, Health & Analytics, Battelle Memorial Institute

Readmission reduction has been a key focus for health care systems and policymakers due to financial penalties faced by hospitals. Penalties are assessed for higher than expected readmission rates among patients hospitalized for several conditions monitored by the CMS. Of these conditions, heart failure has the highest readmission rates among Medicare beneficiaries. This webinar will discuss key policy questions related to the role of innovative technologies in preventing readmissions, using heart failure as a prototype for costly chronic diseases.

Learn More
Cardiovascular Genetic Testing: Cardiomyopathy and Heart Failure

May 29, 2013 (Wednesday) Noon to 1:00 pm (ET)


Mark McDonald, Assistant Vice President, Heart Institute, CCHMC
John Monroe, Senior Business Director, Heart Institute, CCHMC
Rebecca Martins, Business Manager, CCHMC
Nancy White, Business Enhancement Consultant, CCHMC

The Heart Institute Diagnostic Lab (HIDL) at Cincinnati Children’s Hospital Medical Center (CCHMC) will discuss “Cardiovascular Genetic Testing: Cardiomyopathy and Heart Failure”.  A description of the 4-step ordering process including authorization, billing, reporting results and patient interactions will be provided, as well as the difference between internal and external patients in terms of ordering, reporting and billing.  Also covered will be the various genetic panels and associated diagnosis codes used.  Learn about reimbursement rates, resolving reimbursement issues and payor mix.  Documentation requirements for authorizations, billing, and results reporting will also be addressed.  Understand what makes HIDL unique: patient interaction through Genetic Counselors and PhD/MD consultation.

Learn More
Role of Cardiac Biomarkers in Preventing 30-day Readmission in Chronic Heart Failure Patients

April 24, 2013 (Wednesday) Noon to 1:00 pm (ET)


Amy Saenger, PhD, DABCC, Mayo Clinic

The natriuretic peptides have established a role in the diagnosis of heart failure, however, their ability to bridge the gap in prognosis has fallen short, as evidenced by the high 30-day rehospitalization rate.  The evidence for novel cardiac biomarkers that reflect unique and distinct pathways in heart failure has been promising.  As highlighted in some key clinical publications, they provide additional information above and beyond natriuretic peptides, which enables the delivery of timely and focused care that may significantly improve outcomes.  Amy Saenger, Ph.D. from Mayo Clinic will highlight in this webinar the clinical utility of next generation cardiac biomarkers in heart failure management.

Learn More
Peripartum Cardiomyopathy and Heart Failure

March 27, 2013 (Wednesday) Noon to 1:00 pm (ET)


Carol Hansen, RN, MS, CNS, CCRN  Banner Desert Medical Center

If your odds of winning the LOTTO were 1/2000 would you buy a ticket? Odds of developing Peripartum Cardiomyopathy in the last term of pregnancy or postpartum are about 1/2000. Yet, we hear very little about this major problem faced by women. This webinar will:

• Define Peripartum Cardiomyopathy
• Describe the epidemiology of Peripartum Cardiomyopathy
• Compare and contrast the physiological changes of late stage pregnancy with a non-pregnant woman with heart failure
• Discuss treatment modalities for peripartum cardiomyopathy patients
• Identify priorities of care as the patient transitions through the continuum of care

Learn More
Aquapheresis Therapy: Latest Literature and Future Opportunities

February 27, 2013 (Wednesday) Noon to 1:00 pm (ET)


Brian E. Jaski, MD, FACC – San Diego Cardiac Center, Sharp Memorial Hospital

Experience and literature surrounding Aquapheresis therapy are constantly evolving. Join this webinar presented by Dr. Brian Jaski, an AQ prescriber for over 12 years, as he reviews the latest literature and shares tips and experience in achieving the best results.

Learn More
Pediatric Heart Transplantation – Past, Present and Future

February 13, 2013 (Wednesday) Noon to 1:00 pm (ET)


Jonathan N. Johnson, MD -  Mayo Clinic Transplant Center

In this webinar, we will review the history of heart transplantation in children.  We will then look at current indications for heart transplantation in children and adolescents, and examine the latest data on outcomes of heart transplantation.  We will discuss risk factors that may contribute to poor outcomes either while waiting for transplant or after undergoing transplant.  Finally, we will discuss novel therapies on the horizon in pediatric heart transplantation.Presented by: Jonathan N. Johnson, MD -  Mayo Clinic Transplant Center

Learn More
Beyond The Natriuretic Peptides for Management of Heart Failure: An Expert Panel Review of a Novel Biomarker, ST2

January 30, 2013 (Wednesday) Noon to 1:00 pm (ET)


James Januzzi, MD, FACC, FESC, Massachusetts General Hospital
James Snider, Ph.D, Critical Diagnostics
Tony Joseph, MD, The Healthcare Accreditation Colloquium

Heart failure is a chronic progressive illness that challenges the best clinician. Disease progression is often masked by absence of observable clinical changes, while the neuro-hormonal abnormalities continue unabated.  The natriuretic peptides have established a role in the diagnosis of heart failure, however, their ability to bridge the gap in prognosis has fallen short in the management of these patients.  Novel cardiac biomarkers, like ST2, provide additional information that enables the delivery of focused care to those patients needing it most in a timely fashion, which has the potential to significantly improve outcomes.  

Learn More
Antecedents of Heart Failure

January 9, 2013 (Wednesday) Noon to 1:00 pm (ET)


Samuel S. Gidding, MD – Nemours/Alfred I. duPont Hospital for Children

Aside from congenital heart disease, all other individuals who develop heart failure start out with normal hearts. Heart failure is a spectrum of illnesses that funnels through a final common pathway of structural heart changes prior to expression of symptoms. In this webinar, Dr. Gidding reviews conventional risk factors (Stage A) and explores early markers of cardiovascular disease as seen by echocardiogram: LV mass and geometry, LA size, speckle tracking, measure of diastolic function.

Learn More
Finding the Bs

November 28, 2012 (Wednesday) Noon to 1:00 pm (ET)


Heart Failure Staging Workgroup facilitated by Tony Joseph, MD.

All those with heart failure began with normal hearts (except congenital heart defects). A substantial mortality bias is introduced between Stage B and Stage C. With this knowledge, it makes sense to expend resources Òfinding the BÕsÓ even though we know and understand there are criticisms to staging in heart failure.

The Colloquium has created a heart failure screening tool and interpretative algorithm. Over 1000 individuals have been screened. This webinar reviews the literature supporting an effort to screen populations for heart failure. The screening tool will be discussed as well as early results.

Learn More